Novartis Kymriah® demonstrates strong responses in
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 ...
Source: globenewswire.com
Page 12 - Subgroup Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Subgroup Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Subgroup Analysis Today - Breaking & Trending Today
Novartis Pharma AG: Novartis Kymriah demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months
Source: finanznachrichten.de
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...
Source: prnewswire.com
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Source: investegate.co.uk
Amgen Announces New Data Being Presented At ASH 2021
/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society...
Source: prnewswire.com